Zhejiang University: Lymphoma trials
The registry lists 11 Lymphoma studies with Zhejiang University as lead sponsor. 6 are open to participants now and 0 have results posted.
Early Phase 1 8Phase 1 2Phase 2 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphomaRecruitingNCT06633341Early Phase 1
- CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT04609241Early Phase 1
- CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesRecruitingNCT04603872Early Phase 1
- A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological MalignanciesRecruitingNCT04532281Early Phase 1
- A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLRecruitingNCT04532268Early Phase 1
- A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological MalignanciesRecruitingNCT04532203Early Phase 1
- Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell LymphomasCompletedNCT05991973Phase 2
- Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) TherapyStatus unknownNCT05349266Phase 1
- Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant LymphomaStatus unknownNCT05239676Early Phase 1
- An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory LymphomaStatus unknownNCT05208853Early Phase 1
- CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell LymphomaStatus unknownNCT03118180Phase 1/2